Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.
Type:
Grant
Filed:
May 13, 2013
Date of Patent:
January 2, 2018
Assignee:
Gruenenthal GmbH
Inventors:
Stefanie Frosch, Klaus Linz, Klaus Schiene
Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Abstract: The present invention relates to a cosmetic composition and method for making up and/or enhancing the appearance of a keratinous substrate, comprising at least one supramolecular polymer, at least one detackifying ingredient which is a hyperbranched functional polymer, at least one fatty phase ingredient(s) and at least one polyethylene wax. The compositions of the present invention may optionally contain at least one colorant.
Abstract: The present invention relates to a nail polish composition comprising: at least one high gloss film forming agent chosen from a styrene maleic anhydride copolymer; at least one co-film forming agent chosen from an epoxy resin; at least one reactive agent chosen from a combination of a polyalkyleneamine and a polyurethane, at least one polyalkyleneamine, and at least one alkoxysilane comprising at least one solubilizing functional group; at least one solvent chosen from at least one volatile solvent and water; optionally, at least one plasticizer; and optionally, at least one colorant, wherein the composition does not require use of nitrocellulose and can be used to makeup or protect nails.
Type:
Grant
Filed:
October 31, 2011
Date of Patent:
July 25, 2017
Assignee:
L'OREAL
Inventors:
Hy Si Bui, Chunhua Li, Sarah Fairneny, Luis Ortega, Mohamed Kanji, Ram Hariharan
Abstract: A liquid insecticide composition is provided containing a neonicotinoid-based compound, a silicone-based surfactant, and a water-soluble organic solvent. Furthermore, a method is provided for enhancing an insecticidal effect which includes using a silicone-based surfactant in combination with a neonicotinoid-based compound as an insecticidal active ingredient.
Abstract: The present invention relates to a temporary composite scaffold comprising discrete ECM particles formed as a fistula plug. We demonstrate that when using scaffolds containing ECM material, higher concentrations of ECM surprisingly do not give better cell morphology. Concentrations lower than 60% (w/w) are sufficient to obtain the best cell morphology and distribution.
Abstract: An excellent oil-thickening or -gelling agent is provided. The agent is compatible with various oils and can freely control the form or viscosity of oily raw materials or cosmetics by changing the quantity thereof added. The agent contains a novel co-modified organopolysiloxane that contains both a group having a siloxane dendron structure and a hydrophilic group and that preferably has a degree of polymerization of 200 or more. A gel composition containing the co-modified organopolysiloxane is also provided. The gel composition is useful as a base that permits stable and easy preparation of cosmetics having various viscoelasticities and forms. An oil is kept in the form of a gel that has a viscoelasticity falling within the intermediate range between the viscoelasticity of liquid and that of solid. Cosmetics containing the thickening or gelling agent are also provided.
Abstract: The present invention is directed to a suitable topical composition for cosmetic, pharmaceutical or dermatological use. In a particular aspect, it is a stable nanoemulsion whose particles have a narrow size distribution range. In another particular aspect, the invention is directed to an improved process for producing said composition.
Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Abstract: A biocompatible composition for tissue repair or regeneration in mammals comprising one or more glass former compounds selected from the group consisting of B2O3, P2O5, and SiO2 and director elements selected from the group consisting of Cu, Sr, Zn, Fe, Mn, Cr, V, Nb, Mo, W, Ba, Co, S, Al, Ti, Y, Mg, Si and/or Ni to promote in vivo calcium compound formation of calcium carbonate or other calcium compounds other than hydroxyapatite. Upon direct application of the biocompatible composition to a mammalian host, calcium carbonate or other calcium compounds other than hydroxyapatite form upon bioreaction of the composition with bodily fluids.
Type:
Grant
Filed:
July 6, 2012
Date of Patent:
February 7, 2017
Assignee:
The Curators of the University of Missouri
Abstract: Provided is a cosmetic composition which has a structure-recovering property, is transparent, is satisfactory in smoothness when applied to the skin or hair, and has a good feeling in use, which comprises components (A) to (D) as described.
Abstract: The invention relates to dosage forms which contain preparations of poorly water-soluble substances in a polymer matrix of polyether copolymers, said polyether copolymers being obtained by the radically initiated polymerization of a mixture from 30 to 80% by weight of N-vinyl lactam, 10 to 50% by weight of vinyl acetate and 10 to 50% by weight of a polyether, and at least one poorly water-soluble polymer, the poorly water-soluble substance being present in the polymer matrix as an amorphous substance.
Type:
Grant
Filed:
May 11, 2010
Date of Patent:
January 31, 2017
Assignee:
BASF SE
Inventors:
Karl Kolter, Dejan Djuric, Stefan Fischer
Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.
Abstract: Described herein are oral care compositions comprising an orally acceptable carrier; and a film, wherein said film comprises an odor controlling active; a mucoadhesive polymer; a release-rate modulating polymer; a polymeric base; and optionally a flavorant; and wherein said film controls release of said odor controlling active.
Abstract: The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. The methods avoid negative hematologic side effects, including hemolysis and hemolytic anemia, that are associated with oral administration of dapsone.
Abstract: Glass-based angiogenic particles of a biocompatible material which comprises 40 to about 80 wt% borate (B2O3) intermixed into a carrier which is an ointment, cream, or surgical glue.
Type:
Grant
Filed:
September 16, 2013
Date of Patent:
November 8, 2016
Assignee:
The Curators of the University of Missouri
Abstract: The use of water-soluble or water-dispersible copolymers which are obtained by free radical-initiated polymerization of a mixture of i) 30 to 80% by weight N-vinyllactam, ii) 10 to 50% by weight vinylacetate and iii) 10 to 50% by weight of a polyether, with the proviso that the total of i), ii) and iii) is equal to 100% by weight, as binders for producing solid active ingredient-containing dosage forms.
Type:
Grant
Filed:
January 2, 2013
Date of Patent:
September 13, 2016
Assignee:
BASF SE
Inventors:
Kathrin Meyer-Böhm, Rainer Dobrawa, Angelika Maschke, Karl Kolter
Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
Type:
Grant
Filed:
April 19, 2011
Date of Patent:
June 21, 2016
Assignee:
Vecta, Ltd.
Inventors:
Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
Abstract: The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (MRI) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials, carboxymethyl dextran (CM-dextran) is the most efficient in terms of stabilizing the annealed iron oxide nanoparticles and exhibiting contrast effects.
Type:
Grant
Filed:
February 6, 2012
Date of Patent:
May 31, 2016
Assignee:
HANWHA CHEMICAL CORPORATION
Inventors:
Taeghwan Hyeon, Yuanzhe Piao, Yong Il Park
Abstract: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. This invention also relates to a medical device including said biomaterial and to a method of repair or treatment including the filling of cavities in the human face or body.
Type:
Grant
Filed:
February 21, 2007
Date of Patent:
May 17, 2016
Assignee:
Cutanea Life Sciences, Inc.
Inventors:
Elisabeth Laugier, Frank Gouchet, Bernard Grandmontagne